# Gastroenterology (inflammatory bowel disease) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lili Boulanger (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET025-SYN-TD
- Date: 1915-01-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thaddeus Nwankwo-Delacroix, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Odile Marchetti-Rowe, MD

## Reason for consultation

Suspected inflammatory bowel disease in a woman of 21 with four months of right lower abdominal pain, diarrhea, fevers, and weight loss, with iron deficiency anemia and a fecal calprotectin of 1240 ug/g. Ileocolonoscopy, MR enterography, and tuberculosis screening are being arranged. Please see her once they are done to confirm the diagnosis and plan treatment with her. **S**

## History

Ms. Boulanger is seen at the request of Dr. Marchetti-Rowe with four months of right lower abdominal cramping, five or six loose stools a day with one at night, evening fevers, fatigue, and loss of 6 kg. The ileocolonoscopy five days ago showed deep longitudinal ulcers over 15 cm of the terminal ileum and patchy ulcers in the ascending and transverse colon with a spared rectum (SES-CD 14); MR enterography showed 18 cm of inflamed terminal ileum without stricture, fistula, or abscess. She has no perianal, joint, eye, or skin symptoms. She has never smoked. She was told directly that the findings show Crohn disease, a lifelong condition that can be controlled, and asked to hear the treatment choices with their trade-offs. **S**

## Examination

| System | Finding |
|---|---|
| General | Thin and tired; BMI 17.5 |
| Mouth | Two small aphthous ulcers inside the lower lip |
| Abdomen | Tender in the right lower quadrant with fullness but no discrete mass |
| Perianal | No fistula, abscess, or skin tags |

BP 102/64 mmHg; pulse 92 bpm; respirations 16/min; temperature 37.4 °C; oxygen saturation 99% on room air; weight 44.8 kg; BMI 17.5 kg/m². All vital signs are synthetic.

## Data reviewed

Ileocolonoscopy images and report; biopsy histology with acid-fast stain and TB PCR (mycobacterial culture pending); MR enterography; chest X-ray; interferon-gamma release assay; hepatitis B, hepatitis C, HIV, measles, and varicella serology; stool tests and celiac serology; blood counts, iron studies, CRP, albumin, vitamin D, and fecal calprotectin; Dr. Marchetti-Rowe's referral. PHQ-9: 8; GAD-7: 9; ALT: 18 U/L; AST: 20 U/L; Total bilirubin: 0.4 mg/dL; Lumbar spine Z-score (DXA): -1.4; Femoral neck Z-score (DXA): -1.1. All results are synthetic.

## Assessment

1. **Crohn disease of the terminal ileum and colon, Montreal A2 L3 B1, moderate to severe** (K50.80). Long ileal ulcers, skip lesions, a spared rectum, small non-caseating granulomas, and the MR findings confirm Crohn disease. Intestinal tuberculosis can look the same; against it here are a negative interferon-gamma release assay, a normal chest X-ray, no caseating or confluent granulomas, no necrotic nodes, and negative acid-fast stain and TB PCR. That is enough to start treatment, but the mycobacterial culture must be checked when final. Diagnosis before 30, extensive deep ulcers, and weight loss predict a disabling course, so she should start an advanced therapy now. **S**
2. **Choice of therapy**. Options discussed with her: infliximab with azathioprine, adalimumab, ustekinumab, risankizumab, and vedolizumab. She chose risankizumab: effective for induction and maintenance in ileocolonic disease, given as three infusions and then a home injection every eight weeks, without an added immunomodulator and with a low rate of serious infection. The trade-off she accepted is that data in pregnancy are more limited than for anti-TNF drugs. A short prednisone bridge will control symptoms until risankizumab acts. **S**
3. **Screening before immunosuppression**. Tuberculosis screen negative. Hepatitis B surface antigen and core antibody negative, but surface antibody below 10 after an infant series: a booster is advised. Immune to measles and varicella, so no live vaccine is needed and treatment need not wait. **S**
4. **Anemia, nutrition, and bone**. Iron deficiency from blood loss and inflammation is best treated intravenously. Moderate malnutrition needs dietitian support. Vitamin D deficiency, low weight, and a steroid course call for vitamin D, calcium during the steroid, and a baseline DXA. **S**
5. **Targets, fertility, and pregnancy**. The targets are clinical response early, steroid-free remission and a normal CRP by about week 12, a normal fecal calprotectin by about six months, and endoscopic healing at six to twelve months. Crohn disease in remission does not reduce fertility; the main risk to a pregnancy is active disease, so a pregnancy should be planned in remission. **S**

## Recommendations

1. Risankizumab 600 mg intravenously at weeks 0, 4, and 8, then 360 mg subcutaneously every 8 weeks from week 12, with liver enzymes and bilirubin at baseline and through at least week 12.
2. Prednisone 40 mg daily, tapered by 5 mg each week to stop at eight weeks; no further steroid courses without a review of the plan.
3. Review the final mycobacterial culture before the third infusion.
4. Before the first infusion: PCV20, recombinant zoster vaccine dose 1, and a hepatitis B booster, with anti-HBs checked one to two months later; zoster dose 2 two to six months later; inactivated influenza and COVID-19 vaccines each season; no live vaccines.
5. Ferric derisomaltose 1000 mg intravenously with the first infusion; vitamin D3 1889 units daily; calcium while on prednisone; dietitian support with oral supplements; baseline DXA.
6. Treat to target: symptoms and CRP at each visit, fecal calprotectin at about 12 weeks and six months, and ileocolonoscopy at six to twelve months.
7. Contraception while the disease is active; plan any pregnancy after three to six months of steroid-free remission, with a preconception review and folic acid.
8. IBD psychology if her mood or anxiety does not improve, and practical support so she can rehearse and perform.

## Strengths and supports

- Supports: close friends and fellow musicians; her teachers at the conservatory **S**

## Communication

Discussed with Dr. Marchetti-Rowe the same day; Ms. Boulanger has a written summary of her diagnosis, her treatment choice, and the monitoring plan, and agreed to it. **S**

## Follow-up

IBD clinic at the week-4 infusion and at week 12; IBD nurse line between visits. Primary care coordinates vaccines, nutrition, and mood screening. **S**

## Guideline basis

- ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025), American College of Gastroenterology
- AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021 (2021), American Gastroenterological Association
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis 2024;18(10):1531-1555 (2024), European Crohn's and Colitis Organisation
- ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2026 (2026), European Crohn's and Colitis Organisation
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021), International Organization for the Study of Inflammatory Bowel Diseases
- Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2025;23:S1-S60 (2025), Global Consensus Group on Pregnancy in IBD
- SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026), U.S. National Library of Medicine, DailyMed
